However, the company reports strong underlying growth in other regions, led by mid-teens growth in the Americas and South East Asia. £23m of funding headroom gives the company plenty of scope to continue its strong R&D program, diversifying away from dependence on Aivlosin sales in China. Revenue and margin estimates for FY23/24E have been revised as a result of ongoing weakness in the Chinese market and the impact of the sales tax issue revealed earlier this month. However, we continue to see s ....
